The Biotech Growth Trust PLC (the
“Company”)
Compliance with Market Abuse
Regulation
14 October 2022
The Company confirms that:
a) all inside
information which the Directors and Company may have had has been
notified to a Regulated Information Service (“RIS”);
b) the Company’s
net asset value per share is calculated and announced through a RIS
on a daily basis; and
c) the Company
has no reason to believe that there will be any material difference
between the net asset value per share as at close of business on
Friday, 30 September 2022, which was
announced on Monday, 3 October 2022,
and the financial information to be published in the announcement
of its results for the half year ended 30
September 2022.
The Company is, therefore, not prohibited from dealing in its
own securities during the closed period, as defined by the Market
Abuse Regulation, which will end on the date of the publication of
its results for the half year ended 30
September 2022, expected to be on or after 16 November 2022.
-ENDS-
For further information please contact:
Katherine Manson
Frostrow Capital LLP 020 3709 8734